NCT00289510已完成1 期
Single-Blind, Randomized, Controlled Phase I/II Study to Compare the Safety and Immunogenicity of an Inactivated Influenza Vaccine (Whole Virion, Vero Cell Derived) With a License Egg Derived Influenza Vaccine
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 423
- 试验地点
- 6
研究概览
简要总结
The objective of this study is to assess the safety and immunogenicity of inactivated influenza vaccine (whole virion, Vero cell derived). Subjects will be randomly assigned to receive a single injection of whole virion, Vero cell derived or egg derived influenza vaccine on Day 0. Subjects will return to the study site for safety evaluation at predetermined intervals for 180 days after vaccination. Subjects will also have blood drawn at predetermined intervals to measure their immunologic response to vaccination.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Single
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Male and female subjects who
- •are 18 to 45 years of age, inclusive, on the day of screening;
- •have an understanding of the study, agree to its provisions, and give written informed consent prior to study entry;
- •are clinically healthy (in a physical condition such that the physician would have no reservations vaccinating with an influenza vaccine outside the scope of a clinical study);
- •agree to keep a daily record of symptoms;
- •if female and capable of bearing children - have a negative urine pregnancy test result at study entry and agree to employ adequate birth control measures for the duration of the study.
排除标准
- •Subjects who
- •have received any influenza vaccination for the 2005/2006 influenza season and/or the 2004/2005 influenza season;
- •have received any vaccination within 2 weeks prior to vaccination in this study;
- •suffer from any kind of immunodeficiency;
- •suffer from a disease (e.g. autoimmune disease) or are undergoing a form of treatment (e.g. systemic corticosteroids) that can be expected to influence immune response;
- •have a history of inflammatory or degenerative neurological disease (e.g. Guillain Barré, multiple sclerosis);
- •have received a blood transfusion or immunoglobulins within 30 days of study entry;
- •have donated blood or plasma within 30 days of study entry;
- •have a history of any vaccine related contraindicating event (e.g., anaphylaxis, allergy to eggs, allergy to components of the test or comparator vaccine, other known contraindications);
- •have a rash, dermatologic condition or tattoos which may interfere with injection site reaction rating;
- •have a known or suspected problem with alcohol or drug abuse;
- •are unable to lead an independent life as a result of either physical or mental handicap;
- •were administered an investigational drug within six weeks prior to study entry;
- •are concurrently participating in a clinical study that includes the administration of an investigational product;
- •if female, are pregnant or lactating;
- •are a member of the team conducting this study or are in a dependent relationship with the study investigator. Dependent relationships include close relatives (i.e., children, partner/spouse, siblings, parents) as well as employees of the investigator.
研究者
研究点 (6)
Loading locations...
相似试验
已完成
2 期
Comparison of the Safety and Immune Response of an Influenza Vaccine Made by a New Manufacturing Process With a Vaccine Made by the Traditional Manufacturing Process for Season 2003/2004InfluenzaNCT00161837Alachua Government Services, Inc.
已完成
3 期
Safety and Immunogenicity of One Dose of a Surface, Antigen, Inactivated, Influenza Vaccine Produced in Mammalian Cell Culture Administered to Adult and Elderly SubjectsInfluenzaNCT01422512Novartis Vaccines126
已完成
3 期
Clinical Trial to Evaluate the Safety and Immunogenicity of Quadrivalent Influenza Vaccine (7.5μg/0.25ml)Seasonal InfluenzaNCT03859141Sinovac Biotech Co., Ltd2,340
已完成
3 期
Clinical Trial to Evaluate the Safety and Immunogenicity of Quadrivalent Influenza Vaccine (15µg/0.5ml)Seasonal InfluenzaNCT03853993Sinovac Biotech Co., Ltd2,380
已完成
1 期
A/H5N1 Virus-Like Particle Antigen Dose Ranging Study With Adjuvant 1Influenza (Pandemic)NCT01594320Novavax333